TrialNeuro-oncology2023

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.

José Manuel Pérez-García et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.